Aug 2026· European Journal of Surgical Oncology· Vol 52 11, pp.
112098
· 0 citations· 25 references
Medicine
TL;DR
The interval between cancer diagnosis and surgery for femoral metastasis is independently associated with overall survival, and this readily available clinical variable may serve as a complementary factor in preoperative survival assessment and assist in patient counseling and surgical planning.
Abstract
Background
The prognostic significance of the interval between initial cancer diagnosis and development of femoral metastasis requiring surgery remains unclear. This study evaluated the association between this interval and overall survival in patients undergoing surgery for metastatic femoral lesions.
Methods
A retrospective cohort study was conducted among 314 patients treated surgically for metastatic femoral disease at a single center between 2005 and 2019. The primary exposure was the interval between cancer diagnosis and surgery for femoral metastasis: <1 year, 1-5 years, and >5 years. Data included demographics, tumor type, fracture status (actual versus impending), surgical modality, and Karnofsky performance score. Survival was assessed using Kaplan-Meier analysis, log-rank testing, and multivariable Cox regression adjusting for clinical and demographic variables.
Results
Median overall survival was 10 months (IQR 3-28). Survival differed significantly among diagnostic-interval groups (p < 0.001), with median survivals of 14 months in the <1-year group, 7 months in the 1-5-year group, and 14 months in the >5-year group. In multivariable analysis, a 1-5-year interval was associated with higher mortality compared with <1 year (HR = 1.79, 95% CI 1.31-2.43). Lower Karnofsky performance status and actual versus impending fracture were also independently associated with increased mortality.
Conclusions
The interval between cancer diagnosis and surgery for femoral metastasis is independently associated with overall survival. Incorporating this readily available clinical variable may serve as a complementary factor in preoperative survival assessment and assist in patient counseling and surgical planning.
The clinical value of primary tumor resection (PTR) for patients with de novo metastatic follicular thyroid carcinoma (FTC) remains controversial due to insufficient subtype-specific real-world evidence. This study aimed to comprehensively evaluate the association between PTR and survival in patients with metastati...
Pei-Jue You, L. Yin, Xiang-Biao Chen et al.· Scientific Reports· 0 citations
A comprehensive meta-analysis of survival outcomes in CRC patients with PALNM undergoing PALND compared with non-surgical management provides the most comprehensive evidence to date that PALND is associated with a significant survival benefit in selected CRC patients with PALNM.
Wan-Bin He, Jie Dan, Ming-Jie Zhu et al.· Langenbeck's archives of sur...· 0 citations
Background/Aims
Few studies have compared endoscopic therapy (ET) with surgical resection for gastrointestinal stromal tumors (GISTs) measuring 2 to 10 cm in terms of overall survival and cancer-specific survival (CSS). This retrospective cohort study aimed to address this gap using data from the Surveillance, Epidemio...
Shuo Chen, Geng Qin, Ying-Ying Xu et al.· The Turkish Journal of Gastr...· 0 citations
Hepatectomy might provide a survival benefit over interventional and systemic therapy in carefully selected patients with resectable HCC and extrahepatic metastasis, particularly those with lung-only metastasis, preserved liver function, and no PVTT.
Tai-Xin Yang, Zhan Lu, Jie Zhang et al.· iLiver· 0 citations
BACKGROUND
While Western literature identifies age, histological grade, tumor characteristics, and metastasis as key prognostic factors for chondrosarcoma survival, data specifically focusing on the Taiwanese population remain sparse.
METHODS
This retrospective study included patients who were pathologically diagnose...
Sung-Chuan Chao, Wei-Hsin Lin, Shing-Hwa Liu et al.· Journal of the Formosan Medi...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.